TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39763142

Group type: EXPERIMENTAL
Intervention: Coping-Together (self-directed intervention with a workbook and 6 booklets)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coping-Together + lay telephone guidance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stepped-up intervention in Stage 2
Number of subjects: 48
Study: 39763430

Group type: EXPERIMENTAL
Intervention: BIC/F/TAF
Number of subjects: 21

Group type: COMPARATOR
Intervention: DRV/c/F/TAF
Number of subjects: 21
Study: 39763513

Group type: EXPERIMENTAL
Intervention: MIMIC intervention (including triage cards, pocket cards, online training module, patient educational pamphlets, and clinical champions)
Number of subjects: 64
Study: 39763581

Group type: EXPERIMENTAL
Intervention: Intravenous levocarnitine (20 mg/kg body weight, infused over 2-3 min after each hemodialysis session for 24 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral levocarnitine (500 mg three times daily for 24 weeks)
Number of subjects: 83
Study: 39763591

Group type: EXPERIMENTAL
Intervention: EX-02
Number of subjects: 196

Group type: COMPARATOR
Intervention: GV (gel vehicle, placebo)
Number of subjects: 196

Group type: COMPARATOR
Intervention: NSSOC (non-surgical standard of care)
Number of subjects: 196
Study: 39764085

Group type: EXPERIMENTAL
Intervention: Inner Engineering program (Shambhavi Mahamudra Kriya)
Number of subjects: 290
Study: 39764090

Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard eating patterns)
Number of subjects: 0
Study: 39764092

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention to increase paretic propulsion and reduce propulsion asymmetry.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 39764095

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian dysfunction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39764100

Group type: EXPERIMENTAL
Intervention: Preoperative eribulin (1.1 mg/m² for three 21-day cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0
Study: 39764115

Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups
Number of subjects: 0
Study: 39764289

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every 4 weeks on top of standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every 4 weeks
Number of subjects: 120
Study: 39764567

Group type: EXPERIMENTAL
Intervention: Psilocybin therapy (PT) - two 25 mg doses administered orally with psychological support
Number of subjects: 59

Group type: COMPARATOR
Intervention: Escitalopram treatment (ET) - 6-week course with daily doses of 10 mg for three weeks and 20 mg for the subsequent three weeks plus matched psychological support
Number of subjects: 59
Study: 39764571

Group type: EXPERIMENTAL
Intervention: Health apps with gamification
Number of subjects: 10079

Group type: COMPARATOR
Intervention: Non-gamified health apps (control)
Number of subjects: 10079
Study: 39764800

Group type: EXPERIMENTAL
Intervention: Web-based breastfeeding education
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no web-based education)
Number of subjects: 120
Study: 39765128

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension treatments
Number of subjects: 47
Study: 39765160

Group type: EXPERIMENTAL
Intervention: AI-VG intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study: 39765425

Group type: EXPERIMENTAL
Intervention: Kinesiotaping and nerve tendon gliding exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Night splint and nerve tendon gliding exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nerve tendon gliding exercises
Number of subjects: 90
Study: 39765426

Group type: EXPERIMENTAL
Intervention: MyotonPRO measurements of biomechanical properties (tone, stiffness, elasticity) of the abductor pollicis brevis and flexor pollicis brevis muscles
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MyotonPRO measurements of elasticity (logarithmic decrement)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pinch strength assessment using Baseline pinch gauge
Number of subjects: 55
Study: 39765937

Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39766323

Group type: EXPERIMENTAL
Intervention: dihexanoyl-phosphatidyl-THIO (diC6-THIO)
Number of subjects: 0
Study: 39767014

Group type: EXPERIMENTAL
Intervention: Dietary supplement consisting of 400 mg of a standardized extract of the persimmon fruit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39767944

Group type: EXPERIMENTAL
Intervention: Parent assessment of cervical spine rotation preference
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Clinician assessment of cervical spine rotation preference
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Objective assessment of cervical range of motion using IMUs
Number of subjects: 69
Study: 39768384

Group type: EXPERIMENTAL
Intervention: Cosmetic serum containing niacinamide, postbiotics, and peptides
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 39768420

Group type: EXPERIMENTAL
Intervention: Dulaglutide and Dapagliflozin combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPP-4 inhibitor (DPP-4i)
Number of subjects: 0
Study: 39768590

Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh Frozen Plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albumin Replacement
Number of subjects: 0
Study: 39768667

Group type: EXPERIMENTAL
Intervention: Transcatheter repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical procedure
Number of subjects: 0
Study: 39768786

Group type: EXPERIMENTAL
Intervention: AI-Based Application for Automatic Detection of Potential Infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39769201

Group type: EXPERIMENTAL
Intervention: ELA blend
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 0
Study: 39769389

Group type: EXPERIMENTAL
Intervention: CBA-1205 (afucosylated humanized antibody against DLK1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBA-1205 in combination with lenvatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBA-1205
Number of subjects: 0
Study: 39770444

Group type: EXPERIMENTAL
Intervention: Δ8-THCV after oral administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39770949

Group type: EXPERIMENTAL
Intervention: Carnosine 2 g/day for 14 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 39771009

Group type: EXPERIMENTAL
Intervention: Online group intervention (IG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual online nutritional counseling (TAU)
Number of subjects: 0
Study: 39771516

Group type: EXPERIMENTAL
Intervention: Novel Lipid Formulation of Cannabidiol (CBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard formulation of CBD)
Number of subjects: 0
Study: 39772341

Group type: EXPERIMENTAL
Intervention: Biphasic rectangular rTMS (30 sessions, 3000 pulses per session, 120% resting motor threshold)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Monophasic rectangular rTMS (30 sessions, 3000 pulses per session, 120% resting motor threshold)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Biphasic rectangular rTMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Monophasic rectangular rTMS
Number of subjects: 18
Study: 39772364

Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled fibroblast activation protein inhibitor
Number of subjects: 40
Study: 39772606

Group type: EXPERIMENTAL
Intervention: Intraarterial tenecteplase up to 4.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cohort of MT patients (ALLY MT) not receiving intraarterial tenecteplase
Number of subjects: 20
Study: 39772650

Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin
Number of subjects: 0
Study: 39772709

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC); unilateral upper limb; cuff pressure 200 mm Hg, twice daily for 7 days
Number of subjects: 547

Group type: COMPARATOR
Intervention: Sham RIC; cuff pressure 60 mm Hg, same procedure as RIC
Number of subjects: 547
Study: 39772802

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 74
Study: 39773004

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rituximab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous (IV) rituximab
Number of subjects: 50
Study: 39773014

Group type: EXPERIMENTAL
Intervention: Self-management strategies during asthma attacks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recognition of impending asthma attacks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Short-acting β-agonist (SABA) overuse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Understanding of asthma attacks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delay in seeking medical help
Number of subjects: 30
Study: 39773112

Group type: EXPERIMENTAL
Intervention: PTSD treatment strategies
Number of subjects: 0
Study: 39773121

Group type: EXPERIMENTAL
Intervention: Molecular profiling techniques including DNA, RNA, and T-cell receptor sequencing on SBA tissue samples.
Number of subjects: 0
Study: 39773137

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 27
Study: 39773172

Group type: EXPERIMENTAL
Intervention: Daraja intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 39773227

Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 99

Group type: COMPARATOR
Intervention: Access visit
Number of subjects: 99

Group type: COMPARATOR
Intervention: Home visit vs IRF discharge
Number of subjects: 99
Study: 39773251

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention to reduce low-value injury care
Number of subjects: 18
Study: 39773255

Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted surgical reduction
Number of subjects: 57
Study: 39773406

Group type: EXPERIMENTAL
Intervention: SAC therapists providing effective treatment tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and supervision for therapists
Number of subjects: 0
Study: 39773433

Group type: EXPERIMENTAL
Intervention: PA+Dex (Physical Activity + Dexamethasone 4 mg twice daily for the first 7 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PA+PBO (Physical Activity + Placebo)
Number of subjects: 64
Study: 39773460

Group type: EXPERIMENTAL
Intervention: GoldiCare intervention (redistributing weekly workloads)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (usual work)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: GoldiCare intervention
Number of subjects: 125
Study: 39773562

Group type: EXPERIMENTAL
Intervention: Durvalumab (1,500 mg, intravenously, every four weeks for 26 cycles max) plus tremelimumab (75 mg, intravenously, every four weeks for 4 cycles max) plus metronomic oral vinorelbine (40 mg, every three weeks)
Number of subjects: 31
Study: 39773564

Group type: EXPERIMENTAL
Intervention: VB10.16 (3 mg every 3 weeks for 12 weeks, then every 6 weeks) combined with atezolizumab (1,200 mg every 3 weeks for 48 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: VB10.16 combined with atezolizumab
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: VB10.16
Number of subjects: 52
Study: 39773694

Group type: EXPERIMENTAL
Intervention: Medisafe app used for 1 month
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medisafe app reminders
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medisafe app usability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medfriend feature usage
Number of subjects: 30
Study: 39773730

Group type: EXPERIMENTAL
Intervention: Semi-Fowler position
Number of subjects: 240

Group type: COMPARATOR
Intervention: Semi sitting position
Number of subjects: 240

Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Various maternal positions during electronic fetal monitoring
Number of subjects: 240
Study: 39773759

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) for 10 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Assessment of parental distress and illness worries before and after treatment
Number of subjects: 72
Study: 39773784

Group type: EXPERIMENTAL
Intervention: STRATIFYHF artificial intelligence-driven decision support system (DSS)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Home-based monitoring of clinical characteristics and accelerometry (wrist-worn monitor)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Focus groups and semi-structured interviews with healthcare professionals and study participants
Number of subjects: 1600
Study: 39773800

Group type: EXPERIMENTAL
Intervention: Four archetype framework for patients at high risk for opioid use disorder (OUD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Participants fitting archetypes 1-4
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Participants fitting archetypes 5-6
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Participants in all archetypes
Number of subjects: 40
Study: 39773801

Group type: EXPERIMENTAL
Intervention: Structured nurses-led telephone call reminders
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Home-visit reminders led by health extension workers
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Application-based automated short message service text reminders
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard care (oral follow-up advice and a baseline follow-up card)
Number of subjects: 460
Study: 39773822

Group type: EXPERIMENTAL
Intervention: Mindfulness-based meditation and yoga
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 39773824

Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stent (AES)
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Biodegradable-polymer everolimus-eluting stent (EES)
Number of subjects: 2107
Study: 39773829

Group type: EXPERIMENTAL
Intervention: AID strategy combining angiography and intracoronary testing
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: AID strategy
Number of subjects: 317
Study: 39773831

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Warfarin (international normalised ratio goal of 2.0-2.5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DOACs (rivaroxaban and apixaban)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 50
Study: 39773838

Group type: EXPERIMENTAL
Intervention: Antireflux mucosal valvuloplasty (ARMV)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 74
Study: 39773848

Group type: EXPERIMENTAL
Intervention: MOON (serious video game) plus standard pharmacological treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment only)
Number of subjects: 76
Study: 39773866

Group type: EXPERIMENTAL
Intervention: Adhera CARINAE DH intervention in addition to standard care
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 74
Study: 39773886

Group type: EXPERIMENTAL
Intervention: Aspirin-ticagrelor
Number of subjects: 5920

Group type: COMPARATOR
Intervention: Aspirin-clopidogrel
Number of subjects: 5920
Study: 39773922

Group type: EXPERIMENTAL
Intervention: Healthy for Two-Home Visiting
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual home visiting services
Number of subjects: 360
Study: 39773950

Group type: EXPERIMENTAL
Intervention: Patch-based PSG
Number of subjects: 206
Study: 39773953

Group type: EXPERIMENTAL
Intervention: smCPET
Number of subjects: 43

Group type: COMPARATOR
Intervention: structured functional capacity surveys
Number of subjects: 43
Study: 39773995

Group type: EXPERIMENTAL
Intervention: capsulised intestinal microbiota transplant (IMT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: not specified
Number of subjects: 50
Study: 39774314

Group type: EXPERIMENTAL
Intervention: Whole-body MRI
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: cfDNA sequencing
Number of subjects: 107

Group type: COMPARATOR
Intervention: Physical examination and laboratory tests
Number of subjects: 107
Study: 39774313

Group type: EXPERIMENTAL
Intervention: Xalnesiran 100 mg (group 1)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Xalnesiran 200 mg (group 2)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Xalnesiran 200 mg + ruzotolimod 150 mg (group 3)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Xalnesiran 200 mg + pegylated interferon alfa-2a 180 μg (group 4)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Nucleoside or nucleotide analogue alone (group 5)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study: 39774400

Group type: EXPERIMENTAL
Intervention: Screen, Initiate, and Maintain (SIM) intervention including healthcare worker training, clinical reminders, and task-sharing strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIM intervention
Number of subjects: 0
Study: 39774509

Group type: EXPERIMENTAL
Intervention: Pulmonary tele-rehabilitation (PTR)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (HPR)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 180
Study: 39774588

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 39774762

Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 102

Group type: COMPARATOR
Intervention: C5 inhibitor (C5i)
Number of subjects: 102
Study: 39774828

Group type: EXPERIMENTAL
Intervention: 3x ABVD plus radiotherapy (n=208) in RAPID
Number of subjects: 1288

Group type: COMPARATOR
Intervention: 3x ABVD alone (n=211) in RAPID
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: 3-4x ABVD plus radiotherapy (n=556) in H10
Number of subjects: 1288

Group type: COMPARATOR
Intervention: 4-6x ABVD alone (n=303) in H10
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (HRpooled=1.19, 95%CI:1.01-1.35, p=0.005)
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: ABVD plus radiotherapy (HRpooled=1.24, 95%CI:1.05-1.46, p=0.009)
Number of subjects: 1288
Study: 39774855

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C treatment
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 39774865

Group type: EXPERIMENTAL
Intervention: Presence of left ventricular diastolic dysfunction (LVDD)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Improvement of LVDD
Number of subjects: 402

Group type: COMPARATOR
Intervention: No LVDD
Number of subjects: 402
Study: 39774967

Group type: EXPERIMENTAL
Intervention: RBI-4000 at 0.1 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBI-4000 at 1 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBI-4000 at 10 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBI-4000 single administration at 1 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBI-4000 single administration at 10 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All doses of RBI-4000
Number of subjects: 0
Study: 39775037

Group type: EXPERIMENTAL
Intervention: Early TRE
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Late TRE
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Self-selected TRE
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 197
Study: 39775039

Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF-based protocol
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Doppler-based protocol (control)
Number of subjects: 1088
Study: 39775041

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular anaerobic dopamine (A-dopamine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Optimized oral antiparkinsonian therapy
Number of subjects: 9
Study: 39775042

Group type: EXPERIMENTAL
Intervention: Suraxavir marboxil (40 mg)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study: 39775043

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus vibostolimab
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus gebasaxturev
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: pembrolizumab monotherapy
Number of subjects: 66
Study: 39775044

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular B7-H3-targeting CAR T cells
Number of subjects: 21
Study: 39775064

Group type: EXPERIMENTAL
Intervention: cipaglucosidase alfa plus miglustat (cipa + mig)
Number of subjects: 0

Group type: COMPARATOR
Intervention: alglucosidase alfa plus placebo (alg + pbo)
Number of subjects: 0
Study: 39775073

Group type: EXPERIMENTAL
Intervention: In-bed self-exercises based on electromyography sensor feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 0
Study: 39775195

Group type: EXPERIMENTAL
Intervention: Morning bright light therapy (MBLT); 60-min duration; daily over 28-day duration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham: deactivated negative ion generator; 60-min duration; daily over 28-day duration
Number of subjects: 120
Study: 39775226

Group type: EXPERIMENTAL
Intervention: Topical therapy, methotrexate, adalimumab, secukinumab, guselkumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 39775433

Group type: EXPERIMENTAL
Intervention: Awake-Prone Position (≥ 6 hours/day)
Number of subjects: 728